Kwan ATH
Department of Internal Medicine, University of Toronto, Toronto, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
ArticleKetamine
Cognitive effects of ketamine and esketamine treatment for major depressive and bipolar disorder: a systematic review.
ArticleKetamine
Effect of ketamine on reward processing in depressive disorders: a systematic review of neuroimaging studies.
ArticleKetamine
The effect of glutamatergic modulators on sleep behavior and architecture in depressive disorders: A systematic review.
ArticleKetamine
A Global Population-Based Study on the Association Between Ketamine and Esketamine With Suicidality Using WHO VigiBase.
ArticleKetamine
Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implications.
ArticleKetamine
Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis.
ArticleKetamine
A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.
ArticleKetamine
The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS).
ArticleKetamine
The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).
ArticleKetamine
Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.
ArticlePsilocybin
Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.
ArticlePsilocybin